Medicare Part D coverage · clobetasol propionate · RxCUI 861512
clobetasol propionate 0.5 MG/ML Topical Spray
Per the CMS 2026 Part D formulary file, clobetasol propionate 0.5 MG/ML Topical Spray is covered by 247 Medicare Part D plans (4.9% of enrollable products), averaging Tier 3, with prior authorization required on 0% of covering formularies.
- 4.9%
- Plan coverage
- 247
- Plans covering
- T3
- Avg tier
- 0%
- Prior auth required
What the CMS Formulary Data Shows for clobetasol propionate 0.5 MG/ML Topical Spray
Per the CMS 2026 Part D formulary file, clobetasol propionate 0.5 MG/ML Topical Spray (RxNorm concept RXCUI 861512, generic name clobetasol propionate) appears on 20 distinct formulary files spanning 247 Medicare Part D plan offerings - 4.9% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 3.
Real-world access to clobetasol propionate 0.5 MG/ML Topical Spray depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 45% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 1,250,981 Part D beneficiaries filled clobetasol propionate 0.5 MG/ML Topical Spray in 2023, with total plan-and-beneficiary spending of $152,216,122 and an average per-beneficiary annual cost of $121.68. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry clobetasol propionate 0.5 MG/ML Topical Spray today.
Coverage Details
- Formularies covering
- 20
- Plans covering
- 247
- Coverage rate
- 4.9%
- Tier range
- Tier 1 – Tier 4
- Average tier
- Tier 3, Preferred Brand
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 45% of formularies
2023 Medicare Spending
- Beneficiaries
- 1,250,981
- Total spending
- $152,216,122
- Avg per beneficiary
- $121.68
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering clobetasol propionate 0.5 MG/ML Topical Spray
100 Medicare Advantage plans with Part D drug coverage include this drug.
Show the next 30 plans
Showing top 50 of 100 plans.
Frequently Asked Questions
Is clobetasol propionate 0.5 MG/ML Topical Spray covered by Medicare Part D?
Yes, clobetasol propionate 0.5 MG/ML Topical Spray is covered by 247 Medicare Part D plans (4.9% of all Part D formularies).
What tier is clobetasol propionate 0.5 MG/ML Topical Spray on Medicare Part D plans?
clobetasol propionate 0.5 MG/ML Topical Spray averages Tier 3 across Part D plans, ranging from Tier 1 to Tier 4.
Does clobetasol propionate 0.5 MG/ML Topical Spray require prior authorization?
0% of Part D formularies require prior authorization for clobetasol propionate 0.5 MG/ML Topical Spray. Step therapy: 0%. Quantity limits: 45%.
How much does Medicare spend on clobetasol propionate 0.5 MG/ML Topical Spray?
In 2023, total Medicare Part D spending on clobetasol propionate 0.5 MG/ML Topical Spray was $152,216,122, covering 1,250,981 beneficiaries. The average spend per beneficiary was $121.68.
Read our methodology - how this data is sourced, computed, and verified.
Nationwide similar Part D drugs
Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.
Closest average formulary tier
- {1 (aprepitant 125 MG Oral Capsule) / 2 (aprepitant 80 MG Oral Capsule) } Pack T3
- atovaquone 150 MG/ML Oral Suspension T3
- chlorpromazine hydrochloride 10 MG Oral Tablet T3
- nitroglycerin 0.004 MG/MG Rectal Ointment T3
- raltegravir 25 MG Chewable Tablet [Isentress] T3
- risperidone 2 MG Disintegrating Oral Tablet T3
Similar prior-authorization rate
- metronidazole 10 MG/ML Topical Cream [Noritate] 0% PA
- 24 HR minocycline 40 MG Extended Release Oral Capsule [Emrosi] 0% PA
- buspirone hydrochloride 10 MG Oral Capsule [Bucapsol] 0% PA
- diflunisal 375 MG Oral Tablet [Dolobid] 0% PA
- hydrocortisone 1 MG/ML Oral Solution [Khindivi] 0% PA
- indomethacin 50 MG Rectal Suppository [Indocin] 0% PA